Receptor Status and Associated Clinico-Histopathological Characteristics among Women with Breast Cancer in a Ugandan Tertiary Hospital

Receptor Status and Associated Clinico-Histopathological Characteristics among Women with Breast Cancer in a Ugandan Tertiary Hospital

Show other versions (1)

Background: The breast cancer landscape in Uganda is characterized by late disease and poor outcomes. Even though receptor status is an important prognostic factor, it is not routinely conducted in the country. This study was set to describe the oestrogen receptors (ER) status and associated cli...

Full description

Bibliographic Details
Main Authors:	Babalanda JNP, Galukande M, Jombwe JG, Fualal JO
Format:	Article
Language:	English
Published:	Surgical Society of Kenya 2018-10-01
Series:	The Annals of African Surgery
Subjects:	breast cancer advanced stage hormonal receptor status triple negative breast cancer
Online Access:	https://www.annalsofafricansurgery.com/receptor-status-and-associated-clin

Similar Items

Receptor Status and Associated Clinico-Histopathological Characteristics among Women with Breast Cancer in a Ugandan Tertiary Hospital
by: Babalanda JNP, et al.
Published: (2014-07-01)

Male breast cancer: A retrospective review of clinical profile from a tertiary cancer care center of India
by: Dharma Ram, et al.
Published: (2017-01-01)

Clinical and histopathological characteristics associated with patients with triple-negative Breast cancer at a national reference hospital, 2012 - 2018
by: Giuliana Mandujano-Guizado, et al.
Published: (2019-06-01)

Evaluation of Androgen Receptor in Various Molecular Subtypes of Carcinoma Breast and its Relationship with Clinicopathological Parameters: A Retrospective Study
by: Vaishali A Walke, et al.
Published: (2021-01-01)

Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial
by: Shuo Wu, et al.
Published: (2020-05-01)

A clinicopathologic study of triple negative breast cancer
by: Vandana L Gaopande, et al.
Published: (2015-01-01)

Giant Fungated Locally Advanced Breast Carcinoma Responded to Hypofractionated Radiotherapy Combined with Apatinib: A Case Report and Literature Review
by: Liu H, et al.
Published: (2021-01-01)

The role and function of SOX11 in DNA damage in triple-negative breast cancer
by: Lee, Tian Yu
Published: (2019)

Metastatic Breast Cancer and Hormonal Receptor Status among a Group of Women in Sub Saharan Africa
by: Nabawanuka A, et al.
Published: (2018-10-01)

Metastatic Breast Cancer and Hormonal Receptor Status among a Group of Women in Sub Saharan Africa
by: Nabawanuka A, et al.
Published: (2013-07-01)

Characteristics of Patients with Estrogen Receptor (ER)-Negative, Progesterone Receptor (PR)-Negative, and HER2-Negative Invasive Breast Cancer in Dr. Hasan Sadikin General Hospital, Bandung, Indonesia from 2010 to 2011
by: Nadytia Kusumadjayanti, et al.
Published: (2015-09-01)

Secretory carcinoma of the breast: A case report and literature review
by: I-Kai Wu, et al.
Published: (2021-01-01)

Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)
by: Arlindo R. Ferreira, et al.
Published: (2018-01-01)

Metastatic Triple Negative Breast Cancer: The New Era of Thinking
by: Mohammed Amrallah A., et al.
Published: (2021-05-01)

Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities
by: Sylvia Annabel Dass, et al.
Published: (2021-01-01)

Genomic features of rapid versus late relapse in triple negative breast cancer
by: Yiqing Zhang, et al.
Published: (2021-05-01)

A retrospective study of clinico-pathological spectrum of carcinoma breast in a West Delhi, India
by: Jitendra Singh Nigam, et al.
Published: (2014-01-01)

Clinical Initial Response of Neoadjuvant Chemotheraphy in Triple Negative, HER-2, and Luminal Types of Breast Cancer in Denpasar (A Preliminary Study)
by: Kristianto Yuli Yarso, et al.
Published: (2012-01-01)

Clinical Initial Response of Neoadjuvant Chemotheraphy in Triple Negative, HER-2, and Luminal Types of Breast Cancer in Denpasar (A Preliminary Study)
by: Kristianto Yuli Yarso, et al.
Published: (2012-01-01)

Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer
by: Claudio Vernieri, et al.
Published: (2020-03-01)

New chemotherapy options for triple-negative breast cancer (review of literature)
by: M A Sekundova, et al.
Published: (2014-03-01)

Rationally Designed Ruthenium Complexes for Breast Cancer Therapy
by: Golara Golbaghi, et al.
Published: (2020-01-01)

Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing in Women with Breast Cancer in Kampala, Uganda
by: Mlole AT, et al.
Published: (2020-11-01)

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer
by: Qi Zhao, et al.
Published: (2021-06-01)

Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas
by: Arathi A Changavi, et al.
Published: (2015-07-01)

Metaplastic Breast Cancer with Chondroid Differentiation
by: Garima Daga, et al.
Published: (2021-07-01)

Current status and novel directions in triple negative breast cancer patients. Risk factors. Role of the platinum-based chemotherapy
by: Olivia IONESCU, et al.
Published: (2016-06-01)

Low KIBRA Expression Is Associated with Poor Prognosis in Patients with Triple-Negative Breast Cancer
by: So-Woon Kim, et al.
Published: (2021-08-01)

AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer
by: Jiehua He, et al.
Published: (2020-01-01)

Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer
by: Chen B, et al.
Published: (2018-12-01)

Druggable Nucleolin Identifies Breast Tumours Associated with Poor Prognosis That Exhibit Different Biological Processes
by: Flora Nguyen Van Long, et al.
Published: (2018-10-01)

Breast cancer disparities: Frontline strategies, proceedings of the 7 th annual texas conference on health disparities
by: Marilyne Kpetemey, et al.
Published: (2012-01-01)

Androgen receptors: unclear ubiquitious mechanism or the missing key in the triple–negative breast cancer?
by: Ana Tečić-Vuger, et al.
Published: (2020-01-01)

Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease
by: Maria Vittoria Dieci, et al.
Published: (2019-06-01)

Inhibition of DNA Repair Pathways and Induction of ROS Are Potential Mechanisms of Action of the Small Molecule Inhibitor BOLD-100 in Breast Cancer
by: Suzanne Bakewell, et al.
Published: (2020-09-01)

Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India
by: Rekha Vijay Kumar, et al.
Published: (2018-01-01)

Frequency of triple negative breast cancer in referrals patients to an oncology radiotherapy section
by: Maedeh Barahman, et al.
Published: (2021-01-01)

Recent updates in systemic therapy of breast cancer: A brief narrative review
by: Shalabh Arora, et al.
Published: (2021-01-01)

Distinct Microbial Signatures Associated With Different Breast Cancer Types
by: Sagarika Banerjee, et al.
Published: (2018-05-01)

HEREDITARY BREAST CANCER
by: E. M. Bit-Sava, et al.
Published: (2016-02-01)